Avoro Capital Advisors LLC - Q2 2015 holdings

$363 Million is the total value of Avoro Capital Advisors LLC's 31 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 100.0% .

 Value Shares↓ Weighting
FOLD BuyAMICUS THERAPEUTICS INC$64,951,000
+41.8%
4,590,199
+9.0%
17.89%
+1.7%
MRTX BuyMIRATI THERAPEUTICS INC.$31,470,000
+234.5%
1,000,000
+211.7%
8.67%
+140.1%
LBIO BuyLION BIOTECHNOLOGIES INC$26,805,000
+3.0%
2,923,065
+36.0%
7.38%
-26.1%
ONTY BuyONCOTHYREON INC$21,008,000
+187.0%
5,617,003
+25.1%
5.78%
+105.9%
ACAD NewACADIA PHARMACEUTICALS INC$20,731,000495,000
+100.0%
5.71%
AGEN BuyAGENUS - INC$18,979,000
+80.6%
2,199,137
+7.4%
5.23%
+29.6%
VNDA NewVANDA PHARMACEUTICALS INC$18,257,0001,438,693
+100.0%
5.03%
LJPC BuyLA JOLLA PHARMACEUTICAL CO.$15,000,000
+77.6%
611,999
+32.6%
4.13%
+27.5%
IG BuyIGI LABORATORIES INC$11,048,000
+87.8%
1,753,682
+143.3%
3.04%
+34.8%
CLDX NewCELLDEX THERAPEUTICS INC$8,886,000352,350
+100.0%
2.45%
VCYT NewVERACYTE INC$8,450,000758,497
+100.0%
2.33%
INNL BuyINNOCOLL AGsponsored adr$7,277,000
+330.8%
497,422
+121.1%
2.00%
+209.3%
AXGT NewAXOVANT SCIENCES LTD.$6,929,000340,000
+100.0%
1.91%
NewNEURODERM LTD.$5,697,000371,111
+100.0%
1.57%
FLML BuyFLAMEL TECHNOLOGIESsponsored adr$5,674,000
+46.3%
267,747
+24.1%
1.56%
+5.0%
HRTX NewHERON THERAPEUTICS INC$4,674,000150,000
+100.0%
1.29%
ALQA NewALLIQUA BIOMEDICAL INC$4,216,000800,000
+100.0%
1.16%
VCEL BuyVERICEL CORP.$3,868,000
-1.3%
1,083,486
+2.3%
1.06%
-29.2%
ADAP NewADAPTIMMUNE THERAPEUTICS-ADRsponsored adr$3,371,000183,900
+100.0%
0.93%
FBIO NewFORTRESS BIOTECH INC.$3,123,000929,531
+100.0%
0.86%
HTBX BuyHEAT BIOLOGICS INC$2,011,000
+21.6%
335,102
+28.9%
0.55%
-12.8%
BIIB NewBIOGEN INC$1,818,0004,500
+100.0%
0.50%
TRGT BuyTARGACEPT INC$1,639,000
+18.3%
587,315
+26.0%
0.45%
-15.2%
NewSPDR SERIES TRUST - S&P BIOTECHput$770,000350,000
+100.0%
0.21%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2015-08-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
AMICUS THERAPEUTICS INC36Q3 202317.9%
MIRATI THERAPEUTICS INC.35Q3 202317.2%
BIOMARIN PHARMACEUTICAL INC31Q3 20238.0%
SAREPTA THERAPUTICS INC28Q3 202314.8%
ASCENDIS PHARMA28Q3 20239.1%
ARGENX SE26Q3 20239.5%
IOVANCE BIOTHERAPEUTICS INC26Q3 20239.1%
FENNEC PHARMACEUTICALS INC25Q3 20230.4%
MADRIGAL PHARMACEUTICALS INC22Q3 20237.2%
XENON PHARMACEUTICALS INC22Q3 20233.3%

View Avoro Capital Advisors LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Avoro Capital Advisors LLC Q2 2015 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Adverum Biotechnologies, Inc.Sold outFebruary 14, 202300.0%
DICE Therapeutics, Inc.February 14, 20232,525,5555.3%
IOVANCE BIOTHERAPEUTICS, INC.February 14, 20237,020,0004.4%
IVERIC bio, Inc.February 14, 20236,750,0005.0%
Kura Oncology, Inc.February 14, 20233,105,0004.5%
Aadi Bioscience, Inc.September 26, 20222,849,40211.7%
ARENA PHARMACEUTICALS INCFebruary 11, 20221,235,0002.0%
AVADEL PHARMACEUTICALS PLCFebruary 11, 20221,670,0002.9%
FENNEC PHARMACEUTICALS INC.February 11, 20221,200,0004.6%
POINT Biopharma Global Inc.Sold outFebruary 11, 202200.0%

View Avoro Capital Advisors LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-05-15
SC 13G/A2024-04-23
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Avoro Capital Advisors LLC's complete filings history.

Compare quarters

Export Avoro Capital Advisors LLC's holdings